Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells
Open Access
- 21 August 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 5 (1), 13249
- https://doi.org/10.1038/srep13249
Abstract
Glycogen synthase kinase-3 beta (GSK-3β) has been investigated as a therapeutic target for numerous human diseases including cancer because of their diverse cellular functions. Although GSK-3β inhibitors have been investigated as anticancer reagents, precise biological mechanisms remain to be determined. In this study, we investigated the anticancer effects of GSK-3β inhibitors on cancer cell lines and observed centrosome dysregulation which resulted in abnormal mitosis. Mitotic checkpoints sensed the mitotic abnormalities and induced apoptosis. For cells that were inherently resistant to apoptosis, cell death distinct from apoptosis was induced. After GSK-3β inhibitor treatment, these cells exhibited characteristic features of mitotic catastrophe, including distended and multivesiculated nuclei and inappropriate reductions in cyclin B1 expression. This suggested that mitotic catastrophe was an alternative mechanism in cells resistant to apoptosis. Although the role of GSK-3β in centrosomes has not yet been clarified, phosphorylated GSK-3β was localised in centrosomes. From these data, GSK-3β seems to regulate centrosome function. Thus, we propose that centrosome dysregulation is an important mechanism for the anticancer effects of GSK-3β inhibitors and that mitotic catastrophe serves as a safe-guard system to remove cells with any mitotic abnormalities induced by GSK-3β inhibition.This publication has 48 references indexed in Scilit:
- Epigenetic and genetic features of 24 colon cancer cell linesOncogenesis, 2013
- Mitotic catastrophe and cell death induced by depletion of centrosomal proteinsCell Death & Disease, 2013
- Structure‐Guided Design of a Highly Selective Glycogen Synthase Kinase‐3β Inhibitor: a Superior Neuroprotective Pyrazolone Showing Antimania EffectsChemMedChem, 2011
- Simultaneous siRNA Targeting of Src and Downstream Signaling Molecules Inhibit Tumor Formation and Metastasis of a Human Model Breast Cancer Cell LinePLOS ONE, 2011
- GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell lineJournal of Neuro-Oncology, 2010
- GSK3 Regulates Mitotic Chromosomal Alignment through CRMP4PLOS ONE, 2010
- Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinomaBritish Journal of Cancer, 2009
- Mitotic catastrophe and apoptosis induced by docetaxel in hormone‐refractory prostate cancer cellsJournal of Cellular Physiology, 2008
- Control of daughter centriole formation by the pericentriolar materialNature, 2008
- GSK-3 inhibitors induce chromosome instabilityBMC Cell Biology, 2007